Exploration of Biomarkers for Asbestos Exposure and Occurrence of Malignant Mesothelioma Based on the Immunological Effects of Asbestos

Investigation was carried out on the immunological effects of asbestos on individuals and found that asbestos exposure not only reduces the effectiveness of tumor surveillance but also makes asbestos exposed individuals sensitive to tumor development. The continuous experimental exposure of T cells to asbestos has enhanced production of IL-10 and TGF-β. It has also provoked over expression of Bcl-2 with reduced expression of cell-surface CXCR3 and suppressed IFN-γ production with decreased expression of activating receptors such as NKp46 in NK cells. These alterations were also detected in asbestos-exposed patients such as those with pleural plaque or mesothelioma. Such changes in combination with certain markers produced by mesothelioma cells may therefore be considered as an initial screening system for asbestos exposure and developing mesothelioma using peripheral blood.

[1]  M. Pistillo,et al.  Evaluation of Soluble Mesothelin-related Peptide as a Diagnostic Marker of Malignant Pleural Mesothelioma Effusions: Its Contribution to Cytology , 2013, Cancer investigation.

[2]  T. Nakano,et al.  Effect of Asbestos on Anti-Tumor Immunity and Immunological Alteration in Patients with Malignant Mesothelioma , 2012 .

[3]  Y. Kondo,et al.  YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes , 2012, Oncogene.

[4]  H. Pass,et al.  Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. , 2012, The New England journal of medicine.

[5]  Stephen A. Williams,et al.  Early Detection of Malignant Pleural Mesothelioma in Asbestos-Exposed Individuals with a Noninvasive Proteomics-Based Surveillance Tool , 2012, PloS one.

[6]  S. Toyokuni,et al.  Differences and similarities between carbon nanotubes and asbestos fibers during mesothelial carcinogenesis: Shedding light on fiber entry mechanism , 2012, Cancer science.

[7]  G. Reid,et al.  Increased Circulating miR-625-3p: A Potential Biomarker for Patients With Malignant Pleural Mesothelioma , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[8]  H. Matsuzaki,et al.  Resistance to asbestos-induced apoptosis with continuous exposure to crocidolite on a human T cell. , 2012, The Science of the total environment.

[9]  Renelle Myers.  Asbestos-related pleural disease , 2012, Current opinion in pulmonary medicine.

[10]  F. Galateau-Sallé,et al.  Malignant Pleural Mesothelioma: From the Bench to the Bedside , 2012, Respiration.

[11]  A. Scherpereel,et al.  CCL2, Galectin-3, and SMRP Combination Improves the Diagnosis of Mesothelioma in Pleural Effusions , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  J. Neuzil,et al.  Clinical significance of circulating miR-126 quantification in malignant mesothelioma patients. , 2012, Clinical biochemistry.

[13]  H. Matsuzaki,et al.  Asbestos-Induced Cellular and Molecular Alteration of Immunocompetent Cells and Their Relationship with Chronic Inflammation and Carcinogenesis , 2012, Journal of biomedicine & biotechnology.

[14]  D. Sugarbaker,et al.  Expression of Interleukin-4 Receptor Alpha in Human Pleural Mesothelioma Is Associated with Poor Survival and Promotion of Tumor Inflammation , 2012, Clinical Cancer Research.

[15]  K. Jöckel,et al.  Identification of miRNA-103 in the Cellular Fraction of Human Peripheral Blood as a Potential Biomarker for Malignant Mesothelioma – A Pilot Study , 2012, PloS one.

[16]  T. Otsuki,et al.  Decreased CXCR3 expression in CD4+ T cells exposed to asbestos or derived from asbestos-exposed patients. , 2011, American journal of respiratory cell and molecular biology.

[17]  T. Otsuki,et al.  Reduction of CXC chemokine receptor 3 in an in vitro model of continuous exposure to asbestos in a human T-cell line, MT-2. , 2011, American journal of respiratory cell and molecular biology.

[18]  N. Cox,et al.  Germline BAP1 mutations predispose to malignant mesothelioma , 2011, Nature Genetics.

[19]  C. Sander,et al.  The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma , 2011, Nature Genetics.

[20]  J. Soh,et al.  Epigenetic Silencing of MicroRNA-34b/c Plays an Important Role in the Pathogenesis of Malignant Pleural Mesothelioma , 2011, Clinical Cancer Research.

[21]  Y. Kondo,et al.  LATS2 is a tumor suppressor gene of malignant mesothelioma. , 2011, Cancer research.

[22]  T. Nakano,et al.  Suppressive effect of asbestos on cytotoxicity of human NK cells. , 2011, International journal of immunopathology and pharmacology.

[23]  D. Henderson,et al.  Early stages of mesothelioma, screening and biomarkers. , 2011, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[24]  R. Gill.  Imaging of mesothelioma. , 2011, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[25]  T. Nakano,et al.  Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma. , 2011, Respiratory medicine.

[26]  T. Otsuki,et al.  Dysregulation of the immune system caused by silica and asbestos , 2010, Journal of immunotoxicology.

[27]  S. Toyokuni,et al.  Biopersistent fiber-induced inflammation and carcinogenesis: lessons learned from asbestos toward safety of fibrous nanomaterials. , 2010, Archives of biochemistry and biophysics.

[28]  M. Tsao,et al.  Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  T. Otsuki,et al.  Decrease in Phosphorylation of ERK following Decreased Expression of NK Cell-Activating Receptors in Human NK Cell Line Exposed to Asbestos , 2009, International journal of immunopathology and pharmacology.

[30]  H. Kindler,et al.  Malignant pleural mesothelioma: an update on biomarkers and treatment. , 2009, Chest.

[31]  T. Nakano,et al.  Impairment in Cytotoxicity and Expression of NK Cell- Activating Receptors on Human NK Cells following Exposure to Asbestos Fibers , 2009, International journal of immunopathology and pharmacology.

[32]  J. Creaney,et al.  Serum and pleural fluid biomarkers for mesothelioma , 2009, Current opinion in pulmonary medicine.

[33]  S. Skates,et al.  Comparison of Osteopontin, Megakaryocyte Potentiating Factor, and Mesothelin Proteins as Markers in the Serum of Patients with Malignant Mesothelioma , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[34]  Y. Sekido.  Molecular biology of malignant mesothelioma , 2008, Environmental health and preventive medicine.

[35]  M. Maeda,et al.  Diagnostic tumor marker of asbestos-related mesothelioma , 2008, Environmental health and preventive medicine.

[36]  T. Brüning,et al.  Soluble mesothelin-related peptides (SMRP) - high stability of a potential tumor marker for mesothelioma. , 2007, Cancer biomarkers : section A of Disease markers.

[37]  P. Baas.  Optimising survival in malignant mesothelioma. , 2007, Lung cancer.

[38]  T. Nakano,et al.  Immunological effects of silica and asbestos. , 2007, Cellular & molecular immunology.

[39]  M. Copin,et al.  Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment , 2007, Clinical Cancer Research.

[40]  M. Maeda,et al.  Establishment of the enzyme‐linked immunosorbent assay system to detect the amino terminal secretory form of rat Erc/Mesothelin , 2007, Cancer science.

[41]  G. Bepler,et al.  Malignant pleural mesothelioma: a comprehensive review. , 2006, Cancer control : journal of the Moffitt Cancer Center.

[42]  T. Nakano,et al.  Involvement of IL-10 and Bcl-2 in resistance against an asbestos-induced apoptosis of T cells , 2006, Apoptosis.

[43]  Mitchell Ho,et al.  Megakaryocyte Potentiation Factor Cleaved from Mesothelin Precursor Is a Useful Tumor Marker in the Serum of Patients with Mesothelioma , 2006, Clinical Cancer Research.

[44]  A. Ueki,et al.  Alterations of Fas and Fas-Related Molecules in Patients with Silicosis , 2006, Experimental biology and medicine.

[45]  B. Robinson,et al.  Advances in malignant mesothelioma. , 2005, The New England journal of medicine.

[46]  Ronald F. Dodson,et al.  Asbestos: Risk Assessment, Epidemiology, and Health Effects , 2005 .

[47]  Y. Matsuo,et al.  Inhibitory Effects of Anti‐Oxidants on Apoptosis of a Human Polyclonal T‐Cell Line, MT‐2, Induced by an Asbestos, Chrysotile‐A , 2005, Scandinavian journal of immunology.

[48]  Zhandong Liu,et al.  Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. , 2005, The New England journal of medicine.

[49]  V. Roggli,et al.  Pathology of Asbestos-Associated Diseases , 2004, Springer New York.

[50]  E. Hess.  Environmental chemicals and autoimmune disease: cause and effect. , 2002, Toxicology.

[51]  M. Jaurand.  Mechanisms of fiber-induced genotoxicity. , 1997, Environmental health perspectives.

[52]  Y. Shinohara,et al.  Mineral phases and some reexamined characteristics of the International Union Against Cancer standard asbestos samples. , 1996, American journal of industrial medicine.

[53]  S. Jhanwar,et al.  High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[54]  K. Steenland,et al.  Silica exposure and autoimmune diseases. , 1995, American journal of industrial medicine.

[55]  O. Olopade,et al.  p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. , 1994, Cancer research.

[56]  S. Weitzman,et al.  The role of free radicals in asbestos-induced diseases. , 1992, Free radical biology & medicine.

[57]  Ramon Silva Martins,et al.  Malignant pleural mesothelioma. , 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

[58]  R. A. McReynolds,et al.  Immunotoxicology of silica. , 1982, Critical reviews in toxicology.

[59]  Y. Ohtsuki,et al.  Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells , 1981, Nature.

[60]  R. B. Payne,et al.  A Broader Concept of Caplan's Syndrome Related to Rheumatoid Factors , 1962, Thorax.

[61]  A. Caplan.  Rheumatoid Disease and Pneumoconiosis (Caplan's Syndrome) , 1959, Proceedings of the Royal Society of Medicine.